ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

39 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Phase 1Phase 2ITP - Immune Thrombocytopenia

CAR-T cells

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China10 participants1 site · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 CAR-T cell infusion

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Phase 2Lupus Nephritis

Mycophenolate MofetilMycophenolate Mofetil

Children's Hospital Medical Center, Cincinnati105 participants19 sites · United StatesCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Phase 2Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)

BCMA-CD19 CAR-T therapy

Peking University People's Hospital50 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3Psoriatic Arthritis

ZasocitinibActive ComparatorPlacebo

Takeda1,088 participants188 sites · United States, Belgium, BulgariaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants231 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

1–15 of 39

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

39 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Phase 1Phase 2ITP - Immune Thrombocytopenia

CAR-T cells

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China10 participants1 site · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 CAR-T cell infusion

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Phase 2Lupus Nephritis

Mycophenolate MofetilMycophenolate Mofetil

Children's Hospital Medical Center, Cincinnati105 participants19 sites · United StatesCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Phase 2Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)

BCMA-CD19 CAR-T therapy

Peking University People's Hospital50 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3Psoriatic Arthritis

ZasocitinibActive ComparatorPlacebo

Takeda1,088 participants188 sites · United States, Belgium, BulgariaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants231 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

1–15 of 39